Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.82
$0.11(1.56%)
At close: 4:00 PM EDT
$7.82
$0.11(1.56%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous Close$7.16
Volume252.14K
Average Volume (3M)964.77K
Market Cap
$680.30M
Enterprise Value$366.28M
Total Cash (Recent Filing)$323.84M
Total Debt (Recent Filing)$16.59M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 05, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding103,704,810
10 Day Avg. Volume919,590
30 Day Avg. Volume964,769
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.77
Forecast
1Y Price Target
$20.50Price Target Upside162.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Capital BaseModest leverage and a substantial equity base give Aura more financial flexibility than a heavily indebted development-stage biotech. This capital structure can support clinical execution and reduce immediate balance-sheet pressure, although continued losses could still erode that cushion over time.
Phase 3 Trial ProgressFull enrollment in a pivotal trial represents meaningful advancement toward a potential regulatory decision and commercial opportunity in ocular oncology. The FDA Special Protocol Assessment adds defined regulatory alignment, while the program’s focus may concentrate resources behind Aura’s lead candidate.
Extended Cash Runway And Strategic FocusExtending the runway into the first half of 2029 gives Aura more time to generate clinical milestones without requiring immediate financing. Concentrating resources on ocular oncology may also improve capital discipline by prioritizing the company’s most advanced strategic opportunity.
Bears Say
No Revenue And Widening LossesAura remains entirely dependent on development progress rather than operating revenue, and its widening losses show that earnings self-sufficiency is not yet established. The absence of commercial sales leaves future value dependent on clinical success, regulatory approval, and eventual product adoption.
Sustained Cash BurnPersistent and increasing cash consumption raises the amount of capital Aura must secure before reaching potential commercialization. Continued burn can reduce financial flexibility and make future equity issuance or other funding increasingly important to maintain clinical programs and operations.
Dilution And Execution RiskThe larger share authorization materially expands Aura’s ability to raise equity, but also creates greater potential dilution for existing holders. Workforce reductions and senior leadership changes add execution risk as the company prepares for pivotal development and possible commercialization.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $680.30M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Aug 11, 2026. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.105.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.37.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,704,810 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 4.416%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (162.15% Upside)
$20.50 (162.15% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.55%
12-Months-Change
Fundamentals
Return on Equity
-73.18%
Trailing 12-Months
Asset Growth
70.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aura Biosciences Inc
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA Stock 12 Month Forecast
Average Price Target
$20.50
▲(162.15% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Opus Genetics
―
4D Molecular Therapeutics
―
Oculis Holding
―
SpyGlass Pharma
―
Ownership Overview
3.73% Insiders
5.21% Mutual Funds
66.33% Other Institutional Investors
15.31% Public Companies and
Individual Investors